WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): October 11, 2006

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

          Delaware                      000-14879                22-2322400
-----------------------------   ------------------------     -------------------
(State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
      of Incorporation)                                      Identification No.)

 650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
-----------------------------------------------------------    -----------------
        (Address of Principal Executive Offices)                 (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200

          (Former Name or Former Address, if Changed Since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))


     On  October  11,  2006,  Cytogen  Corporation   ("Cytogen")  announced  the
execution of a license agreement with InPharma AS ("InPharma")  granting Cytogen
exclusive  rights for  CAPHOSOL(R)  in North America.  CAPHOSOL,  a topical oral
agent, is a prescription  medical device  indicated in the U.S. as an adjunct to
standard oral care in treating oral  mucositis  caused by radiation or high dose
chemotherapy.   CAPHOSOL   is  also   indicated   for   dryness   of  the  mouth
(hyposalivation) or dryness of the throat  (xerostomia)  regardless of the cause
or whether the conditions are temporary or permanent.

     Under the terms of the agreement,  InPharma will receive upfront fees of $5
million upon the closing of the transaction and an additional $1 million payment
after six months.  In addition,  InPharma will receive royalties and sales-based
milestone  payments.  The transaction  also provides  Cytogen with the option to
acquire the rights to CAPHOSOL for the European and Asian markets.

     Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
copy of the related press release of Cytogen, dated October 11, 2006.


(c) Exhibits.

      Exhibit No.       Description
      -----------       -----------

         99.1           Press Release of Cytogen dated October 11, 2006


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        CYTOGEN CORPORATION

                                        By:/s/ Michael D. Becker
                                           Michael D. Becker
                                           President and Chief Executive Officer

Dated:   October 13, 2006

                                  EXHIBIT INDEX

      Exhibit No.       Description
      -----------       -----------

         99.1           Press Release of Cytogen dated October 11, 2006